Table 3.
Classification of patients grouped by NLR < 2.27 (low-NLR-Group) and NLR ≥2.27 (high-NLR-Group)
| Low-NLR-Group (n = 47) | High-NLR-Group (n = 32) | P-value | |
|---|---|---|---|
| Age (years) | |||
| < 61 | 28 (60%) | 10 (31%) | 0.021* |
| ≥ 61 | 19 (40%) | 22 (69%) | |
| Gender (male) | 26 (55%) | 21 (66%) | 0.48 |
| Myasthenia gravis | 8 (17%) | 7 (22%) | 0.77 |
| WBC (× 109/L) | 7.0 | 8.1 | 0.09 |
| Neoadjuvant therapy | 2 (4%) | 1 (3%) | 0.79 |
| Adjuvant radiotherapy | 29 (62%) | 18 (56%) | 0.65 |
| WHO classification | |||
| A | 3 (6%) | 2 (6%) | 0.39 |
| AB | 15 (32%) | 17 (53%) | |
| B1 | 12 (26%) | 4 (13%) | |
| B2 | 7 (15%) | 4 (13%) | |
| B3 | 10 (21%) | 5 (15%) | |
| Masaoka-Koga stage | |||
| I | 12 (26%) | 9 (28%) | 0.68 |
| II | 23 (49%) | 18 (56%) | |
| III | 11 (23%) | 5 (16%) | |
| IV | 1 (2%) | 0 (0%) | |
| TNM stage | |||
| I | 37 (79%) | 28 (88%) | 0.028* |
| II | 0 (0%) | 2 (6%) | |
| IIIA | 10 (21%) | 1 (3%) | |
| IIIB | 0 (0%) | 1 (3%) | |
Significant data are marked (*)